Spero therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., march 31, 2023 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that on march 23, 2023, the compensation committee of spero's board of directors approved the grant of an aggregate of 95,000 restricted stock unit awards (rsus) to four new employees under the spero therapeutics, inc. 2019 inducement equity incentive plan, as amended, or the 2019 inducement plan. the rsus are being granted as inducements material to the new employees becoming employees of spero in accordance with nasdaq listing rule 5635(c)(4).
SPRO Ratings Summary
SPRO Quant Ranking